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ABBREVIATION LIST 
 
7-AAD = 7-Amino-Actinomycin D 
Ann-V = annexin-V 
BM = bone marrow 
CMV = cytomegalovirus 
EFS = event free survival 
EGFP = enhanced green fluorescent protein 
FACS = fluorescence-activated cell sorting 
FBS = fetal bovine serum 
G418 = geneticin sulphate 
GvHD = graft-versus-host disease 
HIV = human immunodeficiency virus  
IFN = interferon 
i.v. = intravenously 
MGG = May Gruenwald Giemsa 
MHC = major histocompatibility complex 
MM = multiple myeloma 
MSC = mesenchymal stromal cell 
MVD = mean vascular density 
NK = natural killer 
OS = overall survival 
s.c. = subcutaneously 
?-SMA = ?-smooth muscle actin 
TU = transducing unit 
VSV-G = protein G of vescicular stomatitis virus 
vWF = von Willebrand factor
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ABSTRACT 
 
Bone marrow mesenchymal stromal cells (BM-MSCs) may survive and proliferate in the presence 
of cycling neoplastic cells. Exogenously administered MSCs are actively incorporated in the tumor 
as stromal fibroblasts, thus competing with the local mesenchymal cell precursors. For this reason, 
MSCs have been suggested as a suitable carrier for gene therapy strategies, as they can be 
genetically engineered with genes encoding for biologically active molecules, which can inhibit 
tumor cell proliferation and enhance the anti-tumor immune response. 
We used BM-MSCs engineered with the murine interferon-alpha (IFN-?) gene (BM-MSCs/IFN-?) 
to assess in a mouse plasmacytoma model the efficacy of this approach towards neoplastic plasma 
cells. We found that IFN-? can be efficiently produced and delivered inside the tumor 
microenvironment. Subcutaneous multiple administration of BM-MSCs/IFN-? significantly 
hampered the tumor growth in vivo and prolonged the overall survival of mice. The anti-tumor 
effect was associated with enhanced apoptosis of tumor cells, reduction in microvessel density, and 
ischemic necrosis. By contrast, intravenous administration of BM-MSCs/IFN-? did not 
significantly modify the survival of mice, mainly as a consequence of an excessive entrapment of 
injected cells in the pulmonary vessels. 
In conclusion, BM-MSCs/IFN-? are effective in inhibiting neoplastic plasma cell growth; however, 
systemic administration of engineered MSCs still needs to be improved to make this approach 
potentially suitable for the treatment of multiple myeloma. 
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INTRODUCTION 
Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of 
all hematological cancers [1]. Despite the fact that standard chemotherapy is usually effective in 
lowering the disease burden, complete remission is achievable only in a minority of patients, and 
responses are rarely persistent [2]. Several randomized studies have shown the improvement of both 
disease-free and overall survival by using autologous hematopoietic stem cell transplantation as 
compared with standard chemotherapy [3,4]. However, this approach is not curative, because of the 
persistence and ultimate recurrence of chemotherapy-resistant disease. Recent studies based on the 
use of biological agents, such as thalidomide, lenalidomide or bortezomib, expecially when used in 
combination with dexamethasone, have shown that a significantly higher number of patients may 
achieve clinical major responses [5,6]. Allogeneic hematopoietic stem cell transplantation is 
curative for a small subset of patients dev loping graft-versus-myeloma effect, but it is associated 
with significant morbidity and mortality as a consequence of the regimen-related toxicity and 
because of infections and tissue injury due to graft-versus-host disease (GvHD). Thus, MM still 
remains an uncurable disease [7]. The treatment of MM with interferon-alpha (IFN-?) has been 
used for years as maintenance therapy, as it may prolong survival by delaying tumor progression [8]. 
Mesenchymal stromal cells (MSCs) are non-hematopoietic progenitor cells endowed with 
multilineage differentiation potential into various cell types, including fibroblasts, adipocytes, 
osteoblasts, chondrocytes, skeletal and cardiac myocytes and, under specific experimental 
conditions, neural cells [9]. MSCs have powerful regulatory properties towards practically all 
immune effectors, including T, B, NK and dendritic cells, and they can modulate in vivo 
autoreactive immune responses, such as GvHD [10]. MSCs may also support tumor development, 
as they inhibit the specific immunity against neoplastic cells [11,12]. Studies in rodents show an 
initial broad bio-distribution of systemically infused MSCs, followed by a small capacity of long-
term engraftment [13]. However, they may survive and proliferate in the presence of cycling 
neoplastic cells, and are incorporated in tumors as stromal fibroblasts [14], thus competing with the 
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local mesenchymal cell precursors [15]. At the same time, they are capable of promoting metastatic 
dissemination of primary tumors in some animal models [16]. 
MSCs can be a suitable tool for gene therapy strategies [17]. In fact, they can be genetically 
engineered with genes encoding for active molecules that can target specifically cancer cell 
proliferation, reduce MSC immune regulatory properties and eventually enhance the anti-tumor 
immune response. MSC transduction with cDNAs coding for factors with anti-tumor activity, such 
as IFN-? and –?, may represent a promising approach for cancer treatment [14,18]. 
In our study, we transduced mouse bone marrow derived MSCs (BM-MSCs) with IFN-? cDNA 
(BM-MSCs/IFN-?) and we analyzed their effects in vivo in the Sp6 plasmacytoma mouse model, 
which can be either hampered by the onset of specific immune response [19] or favoured by the 
injection of BM-MSCs [12]. 
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MATERIALS AND METHODS 
 
Cell lines 
Sp6 hybridoma cells, derived from the P3/X63-Ag8 mouse plasmacytoma [20], were used for in 
vitro and in vivo experiments in mouse. Sp6 is a Balb/c mouse plasmacytoma induced by mineral 
oil and displaying prevalent peritoneal localization [21], although it can also ultimately localize into 
the bone-marrow (BM) after parenchymal dissemination (SS, personal observation), when injected 
intravenously (i.v.), as described for mouse S107 e X24 plasmacytomas [22]. Sp6 cells are highly 
tumorigenic when injected subcutaneously (s.c.) in syngeneic Balb/c mouse strain [20] and their 
growth is favored in vivo by the presence of MSCs of different sources [12]. Sp6 cells were grown 
in vitro in RPMI 1640 (Gibco Invitrogen Corporation, San Diego, CA, USA) supplemented with 
10% fetal bovine serum (FBS; Euroclone, Pavia, Italy) and 5% L-glutamine (Biochrom AG, Berlin, 
Germany). 
Mouse BM-MSCs were obtained from 7-10 week-old Balb/c (Balb/cByJIco, Charles River Italia, 
Calco, LC, Italy), as previously described [12,23-25]. 
The 293T human kidney cell lines were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA), and grown in DMEM supplemented with 10% FBS. 293T cells were 
used both as vector packaging cells and for titration experiments. 
 
Plasmids 
The human immunodeficiency virus type 1 (HIV-1)-derived lentiviral vectors used in this study 
were generated by exploiting the transient three-plasmid vector-packaging system based on 293T 
cells, as previously described [26]. The construct pRRL-SIN18-cPPT-insert-PRE, expressing either 
the enhanced green fluorescent protein (EGFP) or the murine IFN-? gene from an internal 
cytomegalovirus (CMV) promoter, was used as transfer vector
 
[27]. The genomic RNA was 
packaged in lentiviral particles produced by transfection of pCMV?R8.74, a plasmid carrying the 
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 7 
genes encoding HIV-1 Gag and Pol, and pseudotyped with protein G of vescicular stomatitis virus 
(VSV-G) [28]. 
 
Transduction of BM-MSCs and Sp6 cells 
Lentiviral vectors were generated by transfection of 293T cells with 12 ?g of pRRL-SIN18-cPPT-
insert-PRE, 6 ?g of pCMV?R8.74, and 0.3 ?g of the VSV-G expression construct. The day before 
transfection, 5.0x10
6
 293T cells were seeded in 75-cm
2
 tissue culture flasks. The cultures were 
transfected with plasmid DNA by means of a calcium phosphate precipitation technique. Fresh 
medium was added to the cultures 12-18 hours before the supernatants were collected and filtered 
through 0.45 ?m pore filter. To determine viral titer in experiments with the EGFP-coding lentiviral 
vector, serial dilutions of the filtered supernatants were added to 293 target cells that had been 
previously seeded into 96-well culture plates the day before infection at 4x10
3
 cells per well 
concentration. After 6 hours at 37°C, the supernatant was replaced with fresh medium; 72 hours 
later, EGFP expression was detected by epifluorescence microscopy. The titer, expressed as 
transducing units (TU) per milliliter of supernatant, ranged between 2x10
6
 and 4x10
6
 TU/ml. 
Transduction of BM-MSCs cells was performed with cell-free supernatant with either the EGFP- or 
the murine IFN-?-coding lentiviral vector. To this aim, variable volumes of supernatant, containing 
identical amounts of vector particles, were incubated with 4x10
4
 target cells in 6-well plates for 6 
hours at 37°C. After 72 hours, cells were fixed with phosphate-buffered saline (PBS)-1% 
formaldehyde and analyzed for EGFP expression either by fluorescence-activated cell sorting 
(FACS) or by epifluorescence microscopy. In a set of experiments BM-MSCs were sequentially 
transduced by the EGFP-coding lentiviral vector followed, one week later, by transduction with the 
IFN-?-coding lentiviral vector. 
Sp6 cells transduced through electroporation (250V and 250μF) with the cDNA coding for IFN-? 
(Sp6/IFN-?) were also produced and used as control to check the IFN-? production inside the 
tumor in the absence of BM-MSCs/IFN-?. The selection of transfectants was carried out by 
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 8 
growing cells in the presence of 0.75 mg/ml G418 (Geneticin G418 sulphate, Invitrogen 
Corporation, San Diego (CA) USA).  
Growth capacity, immunophenotype and in vitro multilineage differentiation ability of BM-MSCs 
were tested either before and after transduction, according to previously described methods [29,30]. 
The expression of IFN-R (anti-mIFN-?/? R2, R&D, Minneapolis (MN) USA) by Sp6 cells was 
tested by flow cytometry on in vitro growing cells before and after transduction; no significant 
difference in expression was detected (data not shown).” 
 
Quantification of murine IFN-? protein levels by ELISA  
An ELISA assay (PBL Biomedical Laboratories, Piscataway, NY, USA) was used to quantify the 
levels of murine IFN-? in the supernatants of cells transduced to express the cytokine. The range of 
sensitivity of the assay was 12.5-500 pg/ml; according to the available literature and the 
Manufacturer’s instructions, 10 pg of IFN-? are considered equivalent to 1 IU. 
 
Immunofluorescence analysis and monoclonal antibodies 
Cells were analyzed by immunofluorescence and flow cytometry (FACScalibur, Becton Dickinson-
Pharmigen, Milan, Italy). Sp6 cells were analyzed as previously described
 
[19]. Mouse BM-MSCs 
were studied for the expression of CD11c, CD90, CD105, CD44, CD14, CD80, Fas, Fas-L, CD106, 
MHC class I (H-2
d
), and interferon-gamma (IFN-?)-receptor (CD119). In addition, we assessed the 
absence of CD31, CD45, CD86, and MHC class II (I-A/I-E) expression, as previously described
 
[23,30,31]. CD90 and CD105 were purchased from eBioscience, Frankfurt, Germany. All other 
antibodies were purchased from Becton Dickinson-Pharmigen, Milan, Italy. Detached cells were 
analyzed by flow cytometry (Software CellQuest, FACScalibur, Becton Dickinson-Pharmigen, 
Milan, Italy) and 10
4
 cells were acquired for each sample. 
 
Co-culture experiment and evaluation of apoptosis in vitro 
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 9 
BM-MSCs or BM-MSCs/IFN-? were co-cultured with Sp6 cells to asses their effect on Sp6 
proliferation and survival in vitro. First of all, 75x10
3
 BM-MSCs and BM-MSCs/IFN-? were 
seeded in a 6-well culture plate (Multiwell?, BD, Le Pont De Claix, France) in RPMI 1640 
medium supplemented with 10% FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin (all from 
Gibco, Milan, Italy). After 24 hours, BM-MSCs and BM-MSCs/IFN-?, now forming a 
homogeneous confluent monolayer, were irradiated at 6000 cGy. 75x10
3
 Sp6 cells were then seeded 
on top of them (1:1 ratio), and co-cultured in 4 ml medium for 5 days at 37°C in a 5% CO2 
atmosphere. Experimental conditions included: Sp6 alone, Sp6 + BM-MSCs either in direct contact 
or separated by a Transwell™ filter (pore size: 0.4 ?m filter, BD, Le Pont De Claix, France), Sp6 + 
recombinant IFN-? 120 IU/ml, Sp6 + BM-MSCs + recombinant IFN-? 120 ?U/ml or Sp6 + BM-
MSCs/IFN-? either in direct contact or separated by a Transwell™ filter. Sp6 cells, growing in 
suspension, were collected and stained for Annexin-V (Ann-V), CD45 and 7-Amino-Actinomycin 
D (7-AAD). The fraction of apoptotic (Ann-V-positive/7-AAD-negative) or dead (Ann-V-
positive/7-AAD-positive) Sp6 cells was measured after gating for the CD45
pos
 cell fraction by flow 
cytometry. At least three independent experiments were performed for each condition.  
 
In vivo experiments 
Two months-old Balb/c mice (H-2
d
) were injected subcutaneously (s.c.) with 0.5x10
6
 Sp6 cells (H-
2
d
), resuspended in 0.2 ml of PBS. The dose of 0.5x10
6
 cells is tumorigenic in vivo in 100% of 
syngeneic animals. Different conditions were performed: mice injected with 0.5x10
6
 Sp6 cells 
(n=15); mice injected with 0.5x10
6
 Sp6/IFN-? cells (n=15); mice injected with Sp6 and 0.5x106 
BM-MSCs for one (n=20) or three weekly doses (n=10); mice injected with Sp6 and either i.v., 
once a week, with 0.5x10
6
 BM-MSCs/IFN-? (three doses) or s.c for one (n=20), four (n=35) or 8 
total doses (n=15). All s.c. injections were performed in the same anatomical quarter (usually within 
a radius of 0.5 cm around the first inoculum), as previously described [19]. In order to test in vivo 
engraftment of BM-MSCs inside Sp6 tumor, a subgroup of mice was injected s.c. simultaneously 
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with Sp6 and with either single-transduced BM-MSCs/EGFP or with double-transduced BM-
MSCs/EGFP/IFN-?, s.c. or i.v.  
All animals were then euthanized when the subcutaneously-growing tumoral mass reached a 
maximal diameter of 2 cm (volume = 4.187 cm
3
), or became ulcerated. If signs of pain and fatigue 
became evident in the animals earlier, they were sacrified immediately. We evaluated tumor 
volumes considering Sp6 as growing subcutaneously as a sphere (mm
3
). All in vivo experiments 
were part of a Research Protocol already notified to the Italian Ministry of Health on February 19
th
, 
2008 (Protocol n.030/2006). 
 
Immunohistochemistry and immunofluorescence 
Tumors developing in the mice were excised and snap-frozen in liquid nitrogen in an OCT 
compound (Tissue-Tek, Elkhart, IN, USA). Sections of 5-8 ?m thickness were then cut using a 
cryostat, fixed with cold aceton for 5 minutes, air-dried and stored at -80 °C. In the case of May-
Gruenwald Giemsa (MGG), staining was then performed on PBS-rehydrated slides as per 
Manufacturer’s instructions. In the case of immunofluorescent staining, slides were rehydrated in 
PBS, and antigen retrieval was done by microwaving (400 W for four minutes) in sodium-
citrate/citric acid buffer (pH=6). Primary antibodies were used as follows: ?-smooth muscle actin, 
?-SMA (1:400, Sigma-Aldrich, USA), von Willebrand factor, vWF (1:100, DAKO, Milan, Italy), 
anti-mouse CD4 (1:50, Becton Dickinson-Pharmigen, Milan, Italy), anti-mouse CD8 (1:50, Becton 
Dickinson-Pharmigen, Milan, Italy), anti-asialo GM1 (1:100, Wako Chemical GmbH, Neuss, 
Germany), anti-mouse CD45 (1:40, Becton Dickinson-Pharmigen, Milan, Italy), anti-mouse CD90 
(1:50, Becton Dickinson-Pharmigen, Milan, Italy), anti-IFN-? (1:50, PBL Biomedical Laboratories, 
Piscataway, NY, USA), anti-cleaved caspase 3 (Asp 175) ( 1:100, Cell Signaling, Beverly, MA) and 
anti-IFN-R-type I (CD118) (1:50, Abcam, Cambridge, UK). 
To track BM-MSCs into the tumors after s.c. or i.v. injection, we used double-transduced BM-
MSCs/EGFP/IFN-?. Transfection efficiency and EGFP-espression, measured in vitro, were 
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checked after the transduction and immediately before the injection. To detect EGFP-producing 
cells, tumor sections were stained with a primary rabbit polyclonal anti-EGFP antibody, (1/40, 
Invitrogen Corporation, San Diego, CA, USA), followed by a donkey anti-rabbit FITC-conjugated 
secondary Ab, (1/50, Jackson ImmunoResearch, West Grove, PA, USA). Nuclei were stained with 
DAPI (4',6-diamidino-2-phenylindole), 1 ng/ml, and slides were finally treated with Sudan Black, 
1:1000 in a 70% ethanol solution, to increase contrast. Images were acquired using an automated 
epifluorescent Zeiss Axiovert™ Z1 microscope and analyzed by the imaging software Zeiss 
Axiovision™. 
 
Morphometry 
Tumor sections of 5-8 μm were processed for immunohistochemistry by standard procedures. 
Tumor vessels were labeled using immunofluorescent staining for vWF and ?-SMA. Negative 
controls were performed in all cases by omitting the primary antibody. Mean vascular density 
(MVD) was measured by using a score based on the total sum of the ratios of the two diameters of 
each vessel (MaxDiam/MinDiam) on the total observ d area (samples from three independent 
experiments/group) . Anti-vWF and anti-?-SMA stainings were both used to correctly delimit the 
vessels. Vasculature was assessed randomly in 9 fields at high magnification (200x) for each animal; 
three different animals in each treatment group have been used (Sp6 alone, Sp6 + BM-MSCs, Sp6 + 
BM-MSCs/IFN-? one dose, Sp6 + BM-MSCs/IFN-? 8 doses). 
To detect any difference in IFN
pos
 areas in tumors from animals treated with either single or 
multiple doses of BM-MSCs/IFN-?, the volume of IFN-? producing areas formed by engrafting 
BM-MSCs/IFN-? was assessed by means of sequential digital pictures mapping a total area of 10 
mm
2
 (approximately 20 sequential fields at 200x) in slides stained for IFN-?. Numerical codes were 
used to blindly identify groups of treatments, and areas were manually highlighted by two 
independent operators (MT and FM) and measured using the tools provided by the digital imaging 
software Zeiss Axiovision™. Five different animals in each treatment group have been used (Sp6 + 
Page 12 of 41
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 12 
BM-MSCs/IFN-? one dose, Sp6 + BM-MSCs/IFN-? four doses and Sp6 + BM-MSCs/IFN-? 8 
doses). Mice injected with Sp6 cells alone or with one dose of BM-MSCs were also stained for 
IFN-?, and used as negative controls. 
 
Statistics 
Data are expressed as mean value ± standard deviation (SD). Statistical comparison between 
multiple groups has been carried out using one-way ANOVA and Holm-Sidak test to evaluate 
internal differences between multiple groups. Survival analysis has been carried out using the 
method developed by Kaplan and Meiers, and the log-rank test to compare survival. Specific time 
points were selected as particularly relevant on the basis of biological events or study protocol; at 
these time points differences in tumor incidence were also assessed using ?2 test with Yates 
correction. Differences were considered statistically significant for p values ? 0.05. 
All statistical calculations were performed using Stata™ IC v.10.0 (StataCorp, Texas - USA) for 
Microsoft Windows®. 
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RESULTS  
 
BM-MSCs transduced with IFN-?  cDNA secrete IFN-?  in vitro 
The immunophenotype of BM-MSCs/IFN-? was characterized by the expression of CD106, CD90, 
CD105, CD44 and MHC class I molecules, and the absence of leukocyte (CD45, CD14, CD11c) 
and endothelial cell markers (CD31), as well as of CD86 and MHC class II molecules, as previously 
described for unmanipulated BM-MSCs [23,30-32]. There was no significant difference in the 
immunophenotype of BM-MSCs before and after IFN-? transfection, with the exception of the 
down-modulation of CD80 observed in BM-MSCs/IFN-? (data not shown). Comparison of 
proliferation rate of BM-MSCs and BM-MSCs/IFN-? showed only negligible variations (data not 
shown). When we compared untransduced BM-MSCs and BM-MSCs/IFN-? in terms of in vitro 
differentiation and capability of inhibiting immune responses, we found a comparable multilineage 
differentiation potential in both cell types, as assessed by Oil Red, Alkaline Phosphatase and 
Toluidine Blue staining (Supplementary Figure 2); furthermore, BM-MSCs/IFN-? could inhibit 
specific immune responses mediated by activated T lymphocytes as efficiently as BM-MSCs 
(Supplementary Figure 3). 
IFN-? production by BM-MSCs and BM-MSCs/IFN-? was evaluated by ELISA in culture 
supernatants (n=3). In the case of BM-MSCs, the levels of IFN-? were below the detection limit of 
the assay (12.5 pg/ml) in all samples, whereas IFN-? level in the supernatants of BM-MSCs/IFN-?, 
tested in the same conditions, was 1270.86 ± 308.69 pg/ml. Repeated sampling after four weeks of 
culture showed equivalent levels of IFN-?. On the other hand, the level of IFN-? in the 
supernatants of Sp6/IFN-? cells was 1803.91±400.83 pg/ml.” 
 
BM-MSCs/IFN-?  inhibit the survival of Sp6 cells in vitro 
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Aim of our in vivo study was to have a persistent source of IFN-? inside Sp6 growing tumor; thus, 
we compared the effects of the IFN-? levels reached in the supernatants of in vitro BM-MSCs/IFN-
? + Sp6 cell co-culture with those obtained with comparable concentrations of recombinant IFN-? 
exogeneously added. Supernatant IFN-? mean value was 1155.849?109.93 pg/ml that, according 
to the available literature on the topic, corresponds approximately to 120 IU/ml. This level was 
associated to a theoretical 73% Sp6 viability in our dose-effect curve (Supplementary Figure 1).  
In vitro, BM-MSCs/IFN-? inhibit the survival of Sp6 cells, either in direct contact and in 
Transwell
TM
 conditions (Figure 1). As compared to Sp6 cultured alone (87.81±2.55% n=5), only 
the co-culture with BM-MSCs/IFN-? was capable of exerting statistically significant pro-apoptotic 
effects, either in direct contact (65.72±2.47%, n=6;  P<0.001) or in Transwell
TM
 (58.41±7.58%, n=6; 
P<0.001). All other culture conditions were not statistically different from Sp6 cultured alone. In 
details: Sp6 + BM-MSCs contact 82.19±5.06% (n=6); Sp6 + BM-MSCs Transwell™: 82.16±9.41% 
(n=6); Sp6 + recombinant murine IFN-? 120 ?U/ml 84.23±0.15% (n=3); Sp6 + BM-MSCs + 
recombinant murine IFN-? 120 ?U/ml 77.60±2.34% (n=3). As compared to the addition of 
recombinant IFN-?, the use of BM-MSCs/IFN-? managed to obtain a significantly higher 
inhibition of Sp6 survival in vitro, either in direct contact (P=0.002) or in Transwell
TM
 (P<0.001) 
(Figure 1). 
 
BM-MSCs are efficient tools for gene delivery inside growing tumors 
To assess whether Sp6 cells could be targeted by different kind of transduced BM-MSCs in vivo, 
BM-MSCs were either single-transduced with EGFP or double-transduced with both EGFP and 
IFN-?, and injected s.c. or i.v. into Balb/c mice together with Sp6 cells at the same time. The 
localization of BM-MSCs inside growing tumors was then analyzed using immunofluorescent 
staining for EGFP and IFN-?. Scattered cells and small clusters of EGFPpos BM-MCSs were visible 
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within Sp6 growing masses starting from 14-24 days after the injection (data not shown); the same 
occurred with double-transduced EGFP
pos
/IFN-?pos BM-MSCs, which were associated to longer 
survival of the mice (Figure 2). We further tested the dissemination of both cell types in samples 
taken from the spleen, the liver, the central nervous system and lungs upon either s.c. or i.v. 
administration. We did not detect any EGFP
pos
/IFN-?pos cell outside the tumors after s.c. 
administration. By contrast, following i.v. aministration, most BM-MSCs/EGFP/IFN-? remained 
entrapped inside the pulmonary microcirculation and, to a minor extent, into the spleen, with poorer 
evidence of intratumoral engraftment and therapeutical efficacy (data not shown). For this reason, 
we focused our attention only on the efficacy of BM-MSCs/IFN-? administered s.c. in the site of 
developing Sp6 tumors. 
 
BM-MSCs/IFN-?  inhibit in vivo Sp6 cell growth and increase survival 
Groups of Balb/c mice were injected with Sp6 cells alone or with Sp6 + BM-MSCs/IFN-? s.c. 
(ratio 1:1) in the same anatomical quarter (one, four or 8 weekly doses). On day +14 after treatment, 
all animals injected with Sp6 cells alone or co-injected with different doses of BM-MSCs 
developed tumors. In details: after a single dose of BM-MSCs,  tumor incidence was  100%, with 
mean event free survival (EFS) of 12 days (range 10-14 days); after three doses of BM-MSCs, 
tumor incidence was 100%, with mean EFS of 10 days (range 7-13 days). In this subset, we could 
not administer more than three doses of BM-MSCs, similarly to BM-MSCs/IFN-?, because of the 
early appearance of s.c. rapidly growing tumors: in fact, at day +19, all mice were euthanized 
because the tumors had reached the critical diameter of 2 cm or had become ulcerated. By contrast, 
mice co-injected with Sp6 and weekly doses of BM-MSCs/IFN-? s.c. (one, four or 8 total doses) 
showed a significant delay in the onset of palpable tumors and a trend towards slower tumor 
growth, thus resulting in prolonged EFS (P<0.001) and better overall survival (OS) (P<0.001) 
(Figure 3). In fact, median EFS was 17 days in mice treated with one single dose of BM-
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MSCs/IFN-? s.c. vs 20 days in mice receiving four doses of BM-MSCs/IFN-? s.c. and 64 days in 
mice treated with 8 doses of BM-MSCs/IFN-? s.c. As expected, direct IFN-? transduction of Sp6 
(Sp6/IFN-?) increased median EFS (21 days) as compared to controls, but less efficiently than the 
treatment with 8 doses of BM-MSCs/IFN-? s.c. As a consequence of the effects on tumor onset, 
median OS was also significantly improved by the administration of BM-MSCs/IFN-?. Median OS 
was 19 days in the control animals (range: 18-24 days, n=15) and 17 days in animals receiving 
either one or three doses of unmanipulated BM-MSCs (one dose: range: 14-25 days; three doses: 
range: 13-19 days). It improved up to 30-31 days in mice treated with one or four doses of BM-
MSCs/IFN-? s.c. (range: 21-150 days for one dose; range: 20-150 days for four doses) and up to 77 
days in mice treated with 8 weekly s.c. doses (range: 34-150 days) (Figure 3C). All mice developed 
a palpable tumor at day +90. We observed a trend towards slower tumor growth in the group of 
mice coinjected with Sp6 and BM-MSCs/IFN-? s.c. (one, four and 8 doses), where Sp6 mean 
volume at day +10 was 0.37±0.25 cm
3
 (n=19), 0.37±0.28 cm
3
 (n=14) and 0.34±0.36 cm
3
 (n=10), 
respectively. By comparison, mean volume at the same time point was 1.14±0.28 cm
3
 (n=13) in the 
case of Sp6 injected alone. Sp6 transfection with IFN-? or co-administration of one to three doses 
of unmanipulated BM-MSCs resulted in comparable tumor volumes at day 10 from onset (Sp6/IFN-
?: 1.44±1.55 cm3, n=13; +1 dose BM-MSCs: 2.00±1.61 cm3, n=10; +3 doses BM-MSCs: 1.19±0.64 
cm
3
, n=10). 
Considered together, these data suggest that BM-MSCs transduction with IFN-? gene is capable of 
interfering with BM-MSCs-mediated support of Sp6 tumor development in a statistically significant 
manner (P<0.001) (Figure 3). 
 
 
BM-MSCs/IFN-?  alter tumor architecture 
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We studied tumor architecture by standard staining and immunohistochemistry in treated and 
untreated mice. Tumors developing in Sp6-injected untreated mice were easily identifiable from 
surrounding subcutaneous tissue as masses of densely packed, dysplastic, middle-sized, 
homogeneous cells with a central nucleus and high nucleus/cytoplasmic ratio (Figure 4A). These 
masses were limited by a highly vascularized connective capsule containing high numbers of 
CD90
pos
 cells, an antigen expressed by mesenchymal cells at different levels of differentiation 
(Figure 4D). 
Regardless of treatment, Sp6 tumors appeared homogenously formed by CD45
pos
 cells (Figure 4G, 
J and M), as already known from flow cytometry analysis (data not shown). Scattered CD90
pos
 
cells, most probably tumor-associated fibroblasts, are evident in untreated Sp6 tumors (Figure 4D 
and H), but clusters of CD90
pos
 elements could be identified only after BM-MSCs or BM-
MSCs/IFN-? s.c. injection (Figure 4E, F, K and N). Only in the latter group, these clusters were 
associated with areas, clearly visible also at a MGG staining (Figure 4C, arrow), characterized by 
the loss of homogeneous tumoral architecture due to internal necrosis and to the accumulation of 
cellular debris. All these features were evident also in mice treated with just one dose of BM-
MSCs/IFN-? s.c., even though they were more common and evident in mice treated with 8 weekly 
doses. 
IFN-?pos cells, detected as either scattered elements or as clusters, were virtually absent in Sp6 
tumors injected alone or together with unmanipulated BM-MSCs (Figure 4P and Q). By contrast, 
they were detectable by immunofluorescence in animals treated with either one, four or 8 weekly 
doses of BM-MSCs/IFN-? (Figure 4R), with no statistically significant difference between the 
study groups (data not shown). In treated mice, clusters of IFN-? producing cells were surrounded 
by Sp6 cells undergoing apoptosis, as shown by their positivity for activated caspase-3 (Figure 4R). 
Sp6 cells were recognizable from surrounding environment on the basis of their characteristic large 
dysplastic nucleus with broadly dispersed chromatin pattern. 
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We assessed the expression of IFN-R type I by Sp6 cells after treatment with BM-MSCs/IFN-? as a 
potential escape mechanism during tumor development. However, IFN-R type I did not appear 
significantly downregulated on the surface of Sp6 cells following BM-MSCs/IFN-? administration 
(data not shown). 
We then analyzed the tumor vasculature using a double staining for vWF and ?-SMA to identify 
endothelial and perivascular cells. Complex vasculo-stromal axis were evident only in untreated 
mice (Figure 4I and L); on the contrary, mice treated with BM-MSCs/IFN-? s.c. displayed a very 
simple vasculature, consisting mostly of microvascular structures often lacking evident pericytic 
walls (Figure 4O). Tumors developing in mice treated with BM-MSCs/IFN-? s.c. displayed lower 
mean vasculature density (MVD) as compared to controls: in particular, MVD was 170.66±75.74 
n/mm2 in mice injected once (P<0.001) vs 87.17±53.96 n/mm2 in mice treated with 8 weekly 
injections (P<0.001). Corresponding values of MVD in untreated mice and mice injected with one 
dose of BM-MSCs were 290.98±98.42 n/mm2 and 249.92±116.86 n/mm2, respectively (P=NS). 
Complete statistical evaluation is reported in Table 1. Overall, these findings show that repeated 
doses of BM-MSCs/IFN-? result in a proportional inhibition of tumor angiogenesis, and, 
subsequently, in a corresponding reduction of in vivo tumor growth.  
Finally, we assessed the presence of CD8
pos
, CD4
pos
 T and NK infiltrates inside the Sp6 tumors, in 
treated and untreated mice. In all cases, there was no evidence of infiltration by CD8
pos
 or CD4
pos
 
lymphocytes, or NK cells (data not shown). 
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DISCUSSION 
Different animal models have previously shown that i.v. administered MSCs specifically 
engraft inside the tumor architecture and may support cancer cell growth [14,18]. When engineered 
to produce anti-cancer molecules, MSCs may significantly inhibit tumor development in vitro and 
in vivo [14,18,33-35]. This result has been obtained by injecting MSCs either i.v. in lung cancers or 
metastases or into the feeding arteries of solid tumors (i.e. gliomas) [33-35]. 
Myeloma is a systemic and multifocal disease that develops inside the BM. Neoplastic plasma 
cells are sensitive to IFN-?, which has pleiotropic effects in many tumors, such as melanoma, 
Kaposi’s sarcoma, and renal cancer [36-39], but its systemic effects limit the clinical use. For all 
these reasons we studied in our mouse model of plasmacytoma the effect of intra-tumor delivery of 
BM-MSCs/IFN-? to assess their in situ anti-cancer effect and their efficacy in terms of increase of 
EFS and OS. Unfortunately, i.v. administration was hampered by the important entrapment of 
MSCs inside the lung vessels. Consequently, a scarce number of MSCs could be detected inside 
Sp6 tumor architecture and no therapeutic effect was evident. 
However, the specific engraftment of BM-MSCs was proved by using double-transduced 
BM-MSCs (BM-MSCs/EGFP/IFN-?) injected s.c. together with the inoculation of Sp6 cells. BM-
MSCs/EGFP/IFN-? were able not only to localize specifically into the tumor, but also to produce in 
situ IFN-?, even after the withdrawal of BM-MSCs inoculation. The persistence of BM-MSCs/IFN-
? and the in situ production of IFN-? led to longer EFS, slower tumor growth rate and a dose-
dependent effect on the OS, which was up to 3-fold increased in mice treated with 8 total doses of 
BM-MSCs/IFN-?, as compared to controls that all rapidly developed tumors after receiving Sp6 
cells alone or Sp6 co-injected with unmanipulated BM-MSCs. These findings suggest that a cell 
therapy approach based on the use of BM-MSCs/IFN-? may be effective in MM, once the problem 
of i.v. administration is solved or, at least, tempered. 
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According to literature, direct induction of tumor cells apoptosis, inhibition of local 
angiogenesis, and enhancement of NK infiltration are some of the possible explanation for the anti-
tumor effect observed with IFN-?-based gene therapies [40,41]. In a co-culture system, in vitro, 
BM-MSCs/IFN-? affect Sp6 cell survival and proliferation. In fact, after 5 days of co-culture, the 
number of viable Sp6 cells was significantly lower in the presence of BM-MSCs/IFN-?, thus 
showing Sp6 sensitivity to IFN-?. Similarly, we could assess in vivo a focal increase of apoptosis of 
Sp6 cells surrounding IFN-?-producing clusters of engrafted BM-MSCs/IFN-?. Angiogenesis is 
another factor playing a pivotal role in tumor growth, and a potential target for therapy [42,43]. In 
Sp6 tumors, the role of angiogenesis is shown by the presence of complex vasculo-stromal 
structures, provided of a complete endothelial layer surrounded by pericytes. By contrast, 
developing tumors in BM-MSCs/IFN-?-treated mice displayed a diffuse microvasculature rather 
than a complex vascularization, as shown by the significant MVD reduction; this finding was 
associated with the presence of necrotic areas inside the tumors. On the other hand, no clear 
evidence was observed of a role of immune effector cells, such as NK cells, CD4
pos
 and CD8
pos
 T 
cells, in the anti-tumor effect in vivo. In other words, the therapeutic effect of BM-MSCs/IFN-? 
seems to be predominantly related to the direct pro-apoptotic and anti-angiogenic effect of IFN-?, 
rather than to the triggering of innate or adaptive immunity. 
Although we could never prevent or eradicate completely Sp6 tumors in our model, the 
growth of tumors was significantly delayed by the use of BM-MSCs/IFN-?. Moreover, treated 
animals eventually developing a mass showed a significantly lower tumor growth rate. This is 
particularly relevant if we consider that Sp6 plasmacytoma grows and disseminates more quickly 
than human MM
 
[21]. The mechanisms by which Sp6 tumor eventually develops once BM-
MSCs/IFN-? administration is withdrawn, must be further investigated to significantly improve the 
results obtained. However, the use of combined therapeutic approaches including other effective 
drugs could improve the results obtained with BM-MSCs/IFN-? administration. 
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FIGURE LEGENDS 
 
Figure 1. BM-MSCs/IFN-? inhibit the survival of Sp6 cells in vitro. Mean percentage of viable 
Sp6 cells (Ann-V-negative/7-AAD-negative) at day +5 (mean ± standard deviation). As compared 
to Sp6 cultured alone, only the co-culture with BM-MSCs/IFN-? was capable of exerting a 
statistically significant pro-apoptotic effect, either in direct contact (P<0.001) or in Transwell
TM
 
(P<0.001). Respect to the addition of recombinant IFN-?, the use of BM-MSCs/IFN-? managed to 
obtain a significantly higher inhibition of Sp6 survival in vitro, either in direct contact (P=0.002) or 
in Transwell
TM
 (P<0.001). 
 
Figure 2. Double-transduced BM-MSCs efficiently engraft inside growing tumors and 
maintain a long-lasting production of IFN-? . Tumors of mice injected with Sp6 and BM-
MSCs/EGFP/IFN-? s.c. were analyzed by immunofluorescence for EGFP and IFN-?. IFN-?-
producing cells were detectable within the tumors only in mice treated s.c. with BM-
MSCs/EGFP/IFN-?, and IFN-? was detected within the cells up to 10 weeks after the last 
administration of BM-MSCs/EGFP/IFN-?. The Figure shows a representative case injected s.c. 
with BM-MSCs/EGFP/IFN-?. Nuclei were counterstained with DAPI. (A) blue channel (DAPI) (B) 
green channel (FITC; EGFP). (C) red channel (Cy3; IFN-?). (D) merge (RBG). Bars represent 100 
μm.  
 
Figure 3. Treatment with BM-MSCs/IFN-?  s.c. in vivo reduces tumor growth and delays the 
onset of palpable tumors, prolonging the overall survival of mice. Balb/c mice were injected s.c. 
with 0.5?106 cells of Sp6, Sp6+BM-MSCs either once or for three doses, Sp6 +BM-MSCs/IFN-? 
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(either once or for four or 8 doses) or Sp6/IFN-? transfectant. (A) EFS. (B) tumor growth rate after 
onset (mean volumes). (C) OS. 
 
Figure 4. BM-MSCs/IFN-?  presence determines areas of necrosis inside the tumors and 
induces apoptosis in Sp6 cells. Immunohistochemistry and immunofluorescent analysis of Sp6 
tumors (A, D, G, H, I, P), tumors from mice injected with one dose of BM-MSCs s.c. (B, E, J, K, L, 
Q) and tumors from mice treated with 8 doses of BM-MSCs/IFN-? s.c. (C, F, M, N, O, R). 
(A, B, C) May Grunwald-GIEMSA (MGG) staining. Upon s.c. injection, Sp6 tumors are densely 
packed masses of dysplastic, middle-sized, homogeneous cells with high nucleus/cytoplasmic ratio. 
Necrotic areas within the tumors are present only in mice treated with BM-MSCs/IFN-? s.c. (as 
showed by arrow). 
(D, E, F, H, K, N) Staining with anti-CD90. Scattered CD90
pos
 cells, probably tumor-associated 
fibroblasts, are visible also in untreated Sp6 tumors (D, H), but significant clusters of CD90 cells 
are detected only in mice injected with either BM-MSCs (E, K) or BM-MSCs/IFN-? (F, N). These 
clusters are more frequent in the latter group (F), and areas of intratumoral necrosis are evident only 
in this latter case (C, F, N). 
(G, J, M) Staining with anti-CD45. Regardless of treatment, Sp6 tumors are formed by 
homogeneously CD45
pos
 cells. 
(I, L, O) Staining with anti-vWF (green) and anti-?-SMA (red).  Complex vasculostromal axis, 
formed by vWF
pos
 endothelial cells surrounded by SMA
pos
 pericytes, can be recognized only in Sp6 
tumors either injected alone or together with one dose of BM-MSCs (I, L). On the contrary, 
vasculature consists almost exclusively of very simple vWF
pos
 capillary networks in mice treated 
with BM-MSCs/IFN-? s.c. (O). 
(P, Q, R) Staining for Caspase-3 (green) and IFN-? (red). The engraftment of BM-MSCs/IFN-? 
directly induces apoptosis (Caspase-3
pos
 cells) in surrounding Sp6 cells, recognizable on the basis of 
their characteristic large dysplastic nucleus (R). 
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(A, B, C, D, E, F) Magnification 100x, bars represent 200 μm. (G, H, J, K, M, N) Magnification 
400x, bars represent 200 μm. (I, L, O) Magnification 100-200x, bars represent 200 μm. (P, Q, R) 
Magnification 200x, bars represent 40 μm. Insets represent details at 400x. 
 
 
 
Supplementary Figure 1. Sp6 viability at day 5 with increasing doses of recombinant murine IFN-
? added to culture medium. Mean value ± SD (n=3). 
 
Supplementary Figure 2. BM-MSCs and BM-MSCs/EGFP/IFN-? in vitro differentiation. A-D: 
adipogenic differentiation: differentiating cells are stained by Oil-Red-O in red, and, as expected, 
represent a minority of cultured cells; the same cell types, at a earlier differentiation step 
(preadipoblasts, characterized by more frequent, smaller neutral lipidi vacuoles) are clearly visible 
also when treating BM-MSCs/EGFP/IFN-? with induction medium; E-H osteogenic differentiation; 
ALP staining is coloured in faint red; I-L: chondrogenic differentiation. Differentiation is induced 
on cell pellets; proteoglycan and glicosaminoglycan produced by differentiatin chondroblasts are 
coloured in blue. A-H: magnification 100x. I-L: magnification 200x. 
 
Supplementary Figure 3. Cytotoxity assay performed in presence of BM-MSCs and BM-
MSCs/IFN-?. According to the method previously described in Krampera M. et al. Stem Cell Dev 
2007;16:797-810, splenocytes were collected from mice immunized with 5x106 Sp6/B7 cells and 
co-cultured with their target cells (irradiated Sp6/B7 cells) in presence of either BM-MSCs or BM-
MSCs/IFN-?. Both cell types exerted a comparable reduction of immunological CTL-mediated 
specific lysis (as assessed by 
51
Cr release). 
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TABLE LEGENDS 
Table 1. Mean Vascular Density (MVD) in the study groups. MVD was measured by using a 
score based on the total sum of the ratios of the two diameters of each vessel (MaxDiam/MinDiam) on 
the total observed area (samples from three independent experiments/group). Anti-vWF and anti-?-
SMA stainings were both used to correctly delimit the vessels. Increasingly frequent doses of BM-
MSCs/IFN-? corresponded to increasingly lower MVD (P<0.001). 
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